

Tables Hypertension

Prepared for Sample Pharmaceuticals

File: DemoTab_Hypertension.xlsx
Produced on: 12.01.2011

Produced through: Sample Market Research Ltd.
Contact: John Smith, +44 555 66 77 88



Table of Contents

Q1: Have you already participated in a survey about hypertension during the last two months?	Pg. 3
Q2: Approximately how many hypertension patients do you treat within one average month?	Pg. 4
Q3: How many of your hypertension patients do you treat with each of the therapeutical options mentioned below?	Pg. 5
Q4: Have you recently noticed or received any new information regarding the following therapeutical options?	Pg. 9
Q5: Which was the most relevant information you recently received regarding AT-II antagonists?	Pg. 11
Q6: Through which sources did you recently receive information about AT-II antagonists?	Pg. 12
Q7: For each of the following treatment options, how do you estimate the treatment's acceptability over the next six months?	Pg. 13
QS1: Wave	Pg. 17
QS2: Country	Pg. 17

	TOTAL	Wave						Country														
		Wave 1			Wave 2			Germany			United Kingdom			Italy			Spain					
		a			b			c			d			e			f					
		Abs.	% / ø		Abs.	% / ø	Sign.	Abs.	% / ø	Sign.	Abs.	% / ø	Sign.	Abs.	% / ø	Sign.	Abs.	% / ø	Sign.	Abs.	% / ø	Sign.
1001	Q1: Have you already participated in a survey about hypertension during the last two months?																					
	BASIS	518	100	284	100		234	100		136	100		120	100		140	100		122	100		
1	yes	110	21	65	23		45	19		32	24		18	15	e	40	29	d f	20	16	e	
▼ 2	no	408	79	219	77		189	81		104	76		102	85	e	100	71	d f	102	84	e	

	TOTAL	Wave									Country											
		Wave 1			Wave 2			Germany			United Kingdom			Italy			Spain					
		a			b			c			d			e			f					
		Abs.	% / ø	Sign.	Abs.	% / ø	Sign.	Abs.	% / ø	Sign.	Abs.	% / ø	Sign.	Abs.	% / ø	Sign.	Abs.	% / ø	Sign.			
1002	Q2: Approximately how many hypertension patients do you treat within one average month?																					
	▲ FILTER: No participation in previous surveys acc. to Q1																					
	BASIS	408	100	219	100		189	100		104	100		102	100		100	100		102	100		
	0 patients	3	1	3	1		-	-		2	2		-	-		1	1		-	-		
	1-5 patients	38	9	25	11		13	7		13	13		9	9		8	8		8	8		
	6-10 patients	53	13	41	19	b	12	6	a	15	14		12	12		9	9		17	17		
	11-20 patients	82	20	44	20		38	20		28	27	e	21	21		15	15	c	18	18		
	21-50 patients	115	28	52	24	b	63	33	a	25	24		33	32		36	36	f	21	21	e	
	51-100 patients	82	20	34	16	b	48	25	a	13	13	e f	20	20		24	24	c	25	25	c	
	101 and more patients	35	9	20	9		15	8		8	8		7	7		7	7		13	13		
	Sum	408	17467	219	8248		189	9219		104	3838		102	4189		100	4594		102	4846		
⊙	Average	408	42,8	219	37,7	b	189	48,8	a	104	36,9		102	41,1		100	45,9		102	47,5		
	StDev	408	44,1	219	40,6		189	47,3		104	43,4		102	44,4		100	42,3		102	46,3		

		TOTAL		Wave						Country											
				Wave 1			Wave 2			Germany			United Kingdom			Italy			Spain		
				a			b			c			d			e			f		
				Abs.	% / ø	Sign.	Abs.	% / ø	Sign.	Abs.	% / ø	Sign.	Abs.	% / ø	Sign.	Abs.	% / ø	Sign.	Abs.	% / ø	Sign.
1003	Q3: How many of your hypertension patients do you treat with each of the therapeutical options mentioned below?																				
3_1	AT-II antagonists																				
	BASIS	408	100	219	100		189	100		104	100		102	100		100	100		102	100	
	0 patients	48	12	30	14		18	10		19	18	d e	9	9	c	8	8	c	12	12	
	1-5 patients	105	26	71	32	b	34	18	a	34	33	e f	31	30		20	20	c	20	20	c
	6-10 patients	66	16	33	15		33	17		16	15		17	17		16	16		17	17	
	11-20 patients	76	19	38	17		38	20		15	14		20	20		22	22		19	19	
	21-50 patients	60	15	25	11	b	35	19	a	10	10		18	18		18	18		14	14	
	51-100 patients	46	11	18	8	b	28	15	a	9	9		6	6	f	13	13		18	18	d
	101 and more patients	7	2	4	2		3	2		1	1		1	1		3	3		2	2	
	Sum	408	8930	219	3838		189	5092		104	1689		102	1918		100	2564		102	2759	
⊙	Average	408	21,9	219	17,5	b	189	26,9	a	104	16,2	e f	102	18,8		100	25,6	c	102	27,0	c
	StDev	408	30,0	219	27,0		189	32,6		104	25,2		102	27,9		100	30,9		102	34,5	
	Part in % of all treated hypertension patients	408	51	219	47		189	55		104	44		102	46		100	56		102	57	
3_2	ACE inhibitors																				
	BASIS	408	100	219	100		189	100		104	100		102	100		100	100		102	100	
	0 patients	153	38	99	45	b	54	29	a	47	45	e	36	35		29	29	c	41	40	
	1-5 patients	162	40	86	39		76	40		36	35		47	46		42	42		37	36	
	6-10 patients	47	12	20	9		27	14		13	13		10	10		16	16		8	8	
	11-20 patients	32	8	11	5	b	21	11	a	5	5		6	6		9	9		12	12	
	21-50 patients	12	3	3	1	b	9	5	a	2	2		2	2		4	4		4	4	
	51-100 patients	2	0	-	-		2	1		1	1		1	1		-	-		-	-	
	101 and more patients	-	-	-	-		-	-		-	-		-	-		-	-		-	-	
	Sum	408	1944	219	634		189	1310		104	421		102	451		100	549		102	523	
⊙	Average	408	4,8	219	2,9	b	189	6,9	a	104	4,0		102	4,4		100	5,5		102	5,1	
	StDev	408	9,5	219	5,1		189	12,5		104	9,1		102	11,1		100	8,7		102	8,8	
	Part in % of all treated hypertension patients	408	11	219	8	b	189	14	a	104	11		102	11		100	12		102	11	

		TOTAL		Wave						Country											
				Wave 1			Wave 2			Germany			United Kingdom			Italy			Spain		
				a			b			c			d			e			f		
				Abs.	% / ø	Sign.	Abs.	% / ø	Sign.	Abs.	% / ø	Sign.	Abs.	% / ø	Sign.	Abs.	% / ø	Sign.	Abs.	% / ø	Sign.
3_3	Beta blockers																				
	BASIS	408	100	219	100		189	100		104	100		102	100		100	100		102	100	
	0 patients	244	60	131	60		113	60		59	57		55	54	f	60	60		70	69	d
	1-5 patients	90	22	52	24		38	20		22	21		26	25		19	19		23	23	
	6-10 patients	29	7	13	6		16	8		11	11	f	7	7		8	8		3	3	c
	11-20 patients	22	5	9	4		13	7		4	4		10	10	f	6	6		2	2	d
	21-50 patients	20	5	12	5		8	4		6	6		3	3		7	7		4	4	
	51-100 patients	3	1	2	1		1	1		2	2		1	1		-	-		-	-	
	101 and more patients	-	-	-	-		-	-		-	-		-	-		-	-		-	-	
	Sum	408	1762	219	964		189	798		104	550		102	516		100	446		102	250	
	⊙ Average	408	4,3	219	4,4		189	4,2		104	5,3	f	102	5,1	f	100	4,5		102	2,5	c d
	StDev	408	9,8	219	10,2		189	9,5		104	12,3		102	10,5		100	9,1		102	6,3	
	Part in % of all treated hypertension patients	408	10	219	12		189	9		104	14	f	102	12		100	10		102	5	c
3_4	Diuretics																				
	BASIS	408	100	219	100		189	100		104	100		102	100		100	100		102	100	
	0 patients	206	50	125	57	b	81	43	a	61	59	f	56	55	f	56	56	f	33	32	c d e
	1-5 patients	128	31	64	29		64	34		31	30	f	25	25	f	26	26	f	46	45	c d e
	6-10 patients	40	10	11	5	b	29	15	a	7	7		10	10		11	11		12	12	
	11-20 patients	18	4	7	3		11	6		5	5		5	5		4	4		4	4	
	21-50 patients	11	3	8	4		3	2		-	-	d f	4	4	c	3	3		4	4	c
	51-100 patients	3	1	2	1		1	1		-	-		2	2		-	-		1	1	
	101 and more patients	2	0	2	1		-	-		-	-		-	-		-	-		2	2	
	Sum	408	1894	219	1121		189	773		104	245		102	498		100	313		102	838	
	⊙ Average	408	4,6	219	5,1		189	4,1		104	2,4	f	102	4,9		100	3,1	f	102	8,2	c e
	StDev	408	13,7	219	16,6		189	9,1		104	4,7		102	12,2		100	7,2		102	22,6	
	Part in % of all treated hypertension patients	408	11	219	14		189	8		104	6	f	102	12		100	7	f	102	17	c e

	TOTAL	Wave									Country																		
		Wave 1			Wave 2			Germany			United Kingdom			Italy			Spain												
		a			b			c			d			e			f												
		Abs.	% / ø	Sign.	Abs.	% / ø	Sign.	Abs.	% / ø	Sign.	Abs.	% / ø	Sign.	Abs.	% / ø	Sign.	Abs.	% / ø	Sign.										
3_5	Calcium channel blockers																												
	BASIS	408	100	219	100				189	100				104	100				102	100									
	0 patients	252	62	134	61				118	62				58	56	f		64	63			54	54	f	76	75	c e		
	1-5 patients	90	22	46	21				44	23				27	26	f		21	21			28	28	f	14	14	c e		
	6-10 patients	23	6	11	5				12	6				5	5			5	5			5	5		8	8			
	11-20 patients	17	4	13	6				4	2				5	5			4	4			7	7	f	1	1	e		
	21-50 patients	20	5	11	5				9	5				6	6			6	6			5	5		3	3			
	51-100 patients	5	1	3	1				2	1				3	3			1	1			1	1		-	-			
	101 and more patients	1	0	1	0				-	-				-	-			1	1			-	-		-	-			
	Sum	408	1896	219	1169				189	727				104	606			102	578			100	468		102	244			
	⊙ Average	408	4,6	219	5,3				189	3,8				104	5,8	f		102	5,7			100	4,7		102	2,4	c		
	StDev	408	12,5	219	14,0				189	10,5				104	14,5			102	16,0			100	10,2		102	7,1			
	Part in % of all treated hypertension patients	408	11	219	14	b			189	8	a			104	16	f		102	14	f		100	10		102	5	c d		
3_6	Other therapeutical options																												
	BASIS	408	100	219	100				189	100				104	100				102	100				100	100		102	100	
	0 patients	289	71	164	75				125	66				75	72			71	70			60	60	f	83	81	e		
	1-5 patients	70	17	31	14				39	21				17	16	f		20	20	f		26	26	f	7	7	c d e		
	6-10 patients	22	5	11	5				11	6				5	5			4	4			8	8		5	5			
	11-20 patients	16	4	7	3				9	5				3	3			5	5			5	5		3	3			
	21-50 patients	10	2	5	2				5	3				3	3			2	2			1	1		4	4			
	51-100 patients	1	0	1	0				-	-				1	1			-	-			-	-		-	-			
	101 and more patients	-	-	-	-				-	-				-	-			-	-			-	-		-	-			
	Sum	408	1041	219	522				189	519				104	327			102	228			100	254		102	232			
	⊙ Average	408	2,6	219	2,4				189	2,7				104	3,1			102	2,2			100	2,5		102	2,3			
	StDev	408	7,2	219	7,4				189	6,9				104	9,8			102	6,1			100	4,8		102	7,0			
	Part in % of all treated hypertension patients	408	6	219	6				189	6				104	9			102	5			100	6		102	5			

		TOTAL		Wave						Country												
				Wave 1			Wave 2			Germany			United Kingdom			Italy			Spain			
				a			b			c			d			e			f			
				Abs.	% / ø	Sign.	Abs.	% / ø	Sign.	Abs.	% / ø	Sign.	Abs.	% / ø	Sign.	Abs.	% / ø	Sign.	Abs.	% / ø	Sign.	
1003	Q3*1: How many of your hypertension patients do you treat with each of the therapeutical options mentioned below?																					
	OVERVIEW OF AVERAGE																					
	BASIS	408	100	219	100		189	100		104	100		102	100		100	100		102	100		
3_1	AT-II antagonists	408	21,9	219	17,5	b	189	26,9	a	104	16,2	e f	102	18,8		100	25,6	c	102	27,0	c	
3_2	ACE inhibitors	408	4,8	219	2,9	b	189	6,9	a	104	4,0		102	4,4		100	5,5		102	5,1		
3_5	Calcium channel blockers	408	4,6	219	5,3		189	3,8		104	5,8	f	102	5,7		100	4,7		102	2,4	c	
3_4	Diuretics	408	4,6	219	5,1		189	4,1		104	2,4	f	102	4,9		100	3,1	f	102	8,2	c e	
3_3	Beta blockers	408	4,3	219	4,4		189	4,2		104	5,3	f	102	5,1	f	100	4,5		102	2,5	c d	
3_6	Other therapeutical options	408	2,6	219	2,4		189	2,7		104	3,1		102	2,2		100	2,5		102	2,3		
1003	Q3*2: How many of your hypertension patients do you treat with each of the therapeutical options mentioned below?																					
	OVERVIEW OF PART IN %																					
	BASIS	408	100	219	100		189	100		104	100		102	100		100	100		102	100		
3_1	AT-II antagonists	408	51	219	47		189	55		104	44		102	46		100	56		102	57		
3_2	ACE inhibitors	408	11	219	8	b	189	14	a	104	11		102	11		100	12		102	11		
3_4	Diuretics	408	11	219	14		189	8		104	6	f	102	12		100	7	f	102	17	c e	
3_5	Calcium channel blockers	408	11	219	14	b	189	8	a	104	16	f	102	14	f	100	10		102	5	c d	
3_3	Beta blockers	408	10	219	12		189	9		104	14	f	102	12		100	10		102	5	c	
3_6	Other therapeutical options	408	6	219	6		189	6		104	9		102	5		100	6		102	5		

		TOTAL		Wave						Country												
				Wave 1			Wave 2			Germany			United Kingdom			Italy			Spain			
				a			b			c			d			e			f			
				Abs.	% / ø		Abs.	% / ø	Sign.	Abs.	% / ø	Sign.	Abs.	% / ø	Sign.	Abs.	% / ø	Sign.	Abs.	% / ø	Sign.	Abs.
1004	Q4: Have you recently noticed or received any new information regarding the following therapeutical options?																					
4_1	AT-II antagonists																					
	BASIS	408	100	219	100		189	100		104	100		102	100		100	100		102	100		
▼ 1	yes	98	24	43	20	b	55	29	a	10	10	d e	42	41	c e f	27	27	c d	19	19	d	
2	no	310	76	176	80	b	134	71	a	94	90	d e	60	59	c e f	73	73	c d	83	81	d	
4_2	ACE inhibitors																					
	BASIS	408	100	219	100		189	100		104	100		102	100		100	100		102	100		
1	yes	103	25	59	27		44	23		32	31	d	16	16	c e	31	31	d	24	24		
2	no	305	75	160	73		145	77		72	69	d	86	84	c e	69	69	d	78	76		

		TOTAL		Wave						Country												
				Wave 1			Wave 2			Germany			United Kingdom			Italy			Spain			
				a			b			c			d			e			f			
				Abs.	% / ø		Abs.	% / ø	Sign.	Abs.	% / ø	Sign.	Abs.	% / ø	Sign.	Abs.	% / ø	Sign.	Abs.	% / ø	Sign.	Abs.
4.3	Beta blockers																					
	BASIS	408	100	219	100		189	100		104	100		102	100		100	100		102	100		
1	yes	4	1	-	-	b	4	2	a	2	2		1	1		-	-		1	1		
2	no	404	99	219	100	b	185	98	a	102	98		101	99		100	100		101	99		
4.4	Diuretics																					
	BASIS	408	100	219	100		189	100		104	100		102	100		100	100		102	100		
1	yes	13	3	-	-	b	13	7	a	4	4		5	5		1	1		3	3		
2	no	395	97	219	100	b	176	93	a	100	96		97	95		99	99		99	97		
4.5	Calcium channel blockers																					
	BASIS	408	100	219	100		189	100		104	100		102	100		100	100		102	100		
1	yes	50	12	31	14		19	10		5	5	d f	15	15	c e	4	4	d f	26	25	c e	
2	no	358	88	188	86		170	90		99	95	d f	87	85	c e	96	96	d f	76	75	c e	

		TOTAL		Wave						Country											
				Wave 1			Wave 2			Germany			United Kingdom			Italy			Spain		
				a			b			c			d			e			f		
				Abs.	% / ø	Sign.	Abs.	% / ø	Sign.	Abs.	% / ø	Sign.	Abs.	% / ø	Sign.	Abs.	% / ø	Sign.	Abs.	% / ø	Sign.
1005	Q5: Which was the most relevant information you recently received regarding AT-II antagonists?																				
	▲ FILTER: New information recently received acc. to Q4																				
	BASIS	98	100	43	100		55	100		10	100	ALERT	42	100		27	100	ALERT	19	100	ALERT
	** General	7	7	1	2		6	11		-	-		4	10		3	11		-	-	
3	New active agent / mechanism	4	4	1	2		3	5		-	-		1	2		3	11		-	-	
4	Good experience	3	3	-	-		3	5		-	-		3	7		-	-		-	-	
	** Aspects related to active agent (netto)	50	51	23	53		27	49		8	80		27	64		10	37		5	26	
9	Good bio-availability, good absorption	2	2	2	5		-	-		-	-		-	-		1	4		1	5	
	*** Tolerance	35	36	16	37		19	35		6	60		24	57		3	11		2	11	
18	Good tolerance (general)	18	18	8	19		10	18		1	10		16	38	ef	1	4	d	-	-	d
19	Little side effects	8	8	3	7		5	9		3	30	de	2	5	c	1	4	c	2	11	
21	No dry cough	5	5	3	7		2	4		1	10		4	10		-	-		-	-	
10	Good safety profile	4	4	2	5		2	4		1	10		2	5		1	4		-	-	
	*** Effect, effectiveness	26	27	9	21		17	31		6	60		10	24		7	26		3	16	
12	Stable, long-lasting, retarded effect	15	15	6	14		9	16		5	50	def	7	17	c	1	4	c	2	11	c
13	Rapid effect	6	6	-	-	b	6	11	a	2	20	f	3	7		1	4		-	-	c
11	High effectiveness (general)	5	5	3	7		2	4		-	-		-	-	e	4	15	d	1	5	
14	Increase of life expectancy	1	1	-	-		1	2		-	-		-	-		1	4		-	-	
	** Advantages in application	35	36	18	42		17	31		-	-		13	31		13	48		9	47	
37	Only a single dose required	21	21	6	14		15	27		-	-	ef	6	14		9	33	c	6	32	c
35	Good dosability / various doses	12	12	12	28	b	-	-	a	-	-		8	19		3	11		1	5	
36	Easy handling, convenient administration	3	3	1	2		2	4		-	-		-	-	f	1	4		2	11	d
	** Marketing, image, references	4	4	2	5		2	4		-	-		1	2		1	4		2	11	
44	Information material, ads	3	3	1	2		2	4		-	-		1	2		1	4		1	5	
42	Visit of field sales, good sales reps	1	1	1	2		-	-		-	-		-	-		-	-		1	5	
	** Cost aspect	6	6	2	5		4	7		-	-		3	7		1	4		2	11	
75	Good cost-efficacy ratio	4	4	1	2		3	5		-	-		3	7		1	4		-	-	
47	Low price, low costs for daily therapy	2	2	1	2		1	2		-	-		-	-	f	-	-		2	11	d
98	I don't know, nothing	1	1	-	-		1	2		1	10	d	-	-	c	-	-		-	-	
99	Others	4	4	1	2		3	5		1	10		2	5		-	-		1	5	

	TOTAL	Wave									Country											
		Wave 1			Wave 2			Germany			United Kingdom			Italy			Spain					
		a			b			c			d			e			f					
		Abs.	% / ø	Sign.	Abs.	% / ø	Sign.	Abs.	% / ø	Sign.	Abs.	% / ø	Sign.	Abs.	% / ø	Sign.	Abs.	% / ø	Sign.			
1006	Q6: Through which sources did you recently receive information about AT-II antagonists?																					
>	NOTE: Multiple answers permitted																					
▲	FILTER: New information recently received acc. to Q4																					
	BASIS	98	100	43	100		55	100		10	100	ALERT	42	100		27	100	ALERT	19	100	ALERT	
1	Field representative	48	49	22	51		26	47		3	30		20	48		16	59		9	47		
1	Medical professional journal	38	39	19	44		19	35		-	-	d	29	69	c e f	6	22	d	3	16	d	
1	Printed materials from the pharmaceutical industry	36	37	18	42		18	33		4	40		16	38		7	26		9	47		
1	Congresses, symposiums, expert conferences	29	30	13	30		16	29		1	10		14	33		8	30		6	32		
1	Advanced training courses (CME)	15	15	9	21		6	11		-	-		9	21		3	11		3	16		
1	Working groups, informal professional communication/ exchange	18	18	8	19		10	18		-	-		7	17		8	30		3	16		
1	Independent sources of information on the internet (professional associations etc.)	12	12	7	16		5	9		-	-		5	12		4	15		3	16		
1	Websites or electronic newsletters of pharmaceutical companies, product websites	8	8	5	12		3	5		2	20		3	7		1	4		2	11		
1	Others	3	3	1	2		2	4		1	10		2	5		-	-		-	-		

	TOTAL	Wave						Country													
		Wave 1			Wave 2			Germany			United Kingdom			Italy			Spain				
		a			b			c			d			e			f				
		Abs.	% / ø	Sign.	Abs.	% / ø	Sign.	Abs.	% / ø	Sign.	Abs.	% / ø	Sign.	Abs.	% / ø	Sign.	Abs.	% / ø	Sign.		
1007	Q7: For each of the following treatment options, how do you estimate the treatment's acceptability over the next six months?																				
7.1	AT-II antagonists																				
	BASIS	408	100	219	100		189	100		104	100		102	100		100	100		102	100	
1	(1) decrease strongly	3	1	1	0		2	1		1	1		2	2		-	-		-	-	
2	(2) ...	17	4	7	3		10	5		5	5		5	5		2	2		5	5	
3	(3) ...	24	6	13	6		11	6		7	7		5	5		6	6		6	6	
4	(4) ...	174	43	96	44		78	41		36	35	d f	54	53	c e	30	30	d f	54	53	c e
5	(5) ...	77	19	47	21		30	16		21	20		15	15		25	25		16	16	
6	(6) ...	80	20	41	19		39	21		18	17	e	15	15	e	29	29	c d	18	18	
7	(7) increase strongly	33	8	14	6		19	10		16	15	d f	6	6	c	8	8		3	3	c
	Top-Two (6-7)	113	28	55	25		58	31		34	33	d f	21	21	c e	37	37	d f	21	21	c e
	Low-Two (1-2)	20	5	8	4		12	6		6	6		7	7		2	2		5	5	
⊙	Average	408	4,7	219	4,6		189	4,7		104	4,8	d f	102	4,4	c e	100	5,0	d f	102	4,4	c e
	StDev	408	1,2	219	1,2		189	1,3		104	1,4		102	1,2		100	1,2		102	1,1	
7.2	ACE inhibitors																				
	BASIS	408	100	219	100		189	100		104	100		102	100		100	100		102	100	
1	(1) decrease strongly	5	1	2	1		3	2		1	1		1	1		3	3		-	-	
2	(2) ...	20	5	13	6		7	4		5	5		5	5		8	8	f	2	2	e
3	(3) ...	47	12	24	11		23	12		22	21	e f	15	15	f	8	8	c f	2	2	c d e
4	(4) ...	171	42	82	37	b	89	47	a	38	37	f	43	42		35	35	f	55	54	c e
5	(5) ...	93	23	51	23		42	22		27	26		23	23		20	20		23	23	
6	(6) ...	59	14	37	17		22	12		11	11		13	13		17	17		18	18	
7	(7) increase strongly	13	3	10	5		3	2		-	-	e	2	2	e	9	9	c d f	2	2	e
	Top-Two (6-7)	72	18	47	21	b	25	13	a	11	11	e	15	15	e	26	26	c d	20	20	
	Low-Two (1-2)	25	6	15	7		10	5		6	6		6	6		11	11	f	2	2	e
⊙	Average	408	4,4	219	4,5		189	4,3		104	4,1	f	102	4,3	f	100	4,5		102	4,6	c d
	StDev	408	1,2	219	1,2		189	1,1		104	1,1		102	1,1		100	1,5		102	0,9	

		TOTAL		Wave						Country												
				Wave 1			Wave 2			Germany			United Kingdom			Italy			Spain			
				a			b			c			d			e			f			
		Abs.	% / ø		Abs.	% / ø	Sign.	Abs.	% / ø	Sign.	Abs.	% / ø	Sign.	Abs.	% / ø	Sign.	Abs.	% / ø	Sign.	Abs.	% / ø	Sign.
7_3	Beta blockers																					
	BASIS	408	100	219	100		189	100		104	100		102	100		100	100		102	100		
1	(1) decrease strongly	7	2	2	1		5	3		-	-	e	-	-	e	7	7		c d f	-	-	e
2	(2) ...	13	3	6	3		7	4		3	3		5	5	f	5	5		f	-	-	d e
3	(3) ...	44	11	23	11		21	11		18	17	e	11	11		5	5		c	10	10	
4	(4) ...	209	51	116	53		93	49		44	42	d	62	61	c e	46	46		d	57	56	
5	(5) ...	66	16	36	16		30	16		28	27	d f	11	11	c	17	17			10	10	c
6	(6) ...	56	14	30	14		26	14		8	8	f	12	12	f	12	12		f	24	24	c d e
7	(7) increase strongly	13	3	6	3		7	4		3	3		1	1	e	8	8		d f	1	1	e
	Top-Two (6-7)	69	17	36	16		33	17		11	11	f	13	13	f	20	20			25	25	c d
	Low-Two (1-2)	20	5	8	4		12	6		3	3	e	5	5	f	12	12		c f	-	-	d e
⊙	Average	408	4,3	219	4,3		189	4,3		104	4,3		102	4,2	f	100	4,3			102	4,5	d
	StDev	408	1,1	219	1,1		189	1,2		104	1,0		102	1,0		100	1,5			102	1,0	
7_4	Diuretics																					
	BASIS	408	100	219	100		189	100		104	100		102	100		100	100		102	100		
1	(1) decrease strongly	12	3	8	4		4	2		2	2		4	4		4	4			2	2	
2	(2) ...	46	11	27	12		19	10		8	8		11	11		15	15			12	12	
3	(3) ...	73	18	40	18		33	17		22	21		19	19		13	13			19	19	
4	(4) ...	187	46	93	42		94	50		36	35	d e	60	59	c f	49	49		c	42	41	d
5	(5) ...	52	13	30	14		22	12		29	28	d e f	4	4	c	9	9		c	10	10	c
6	(6) ...	31	8	16	7		15	8		6	6	f	4	4	f	6	6		f	15	15	c d e
7	(7) increase strongly	7	2	5	2		2	1		1	1		-	-	e	4	4		d	2	2	
	Top-Two (6-7)	38	9	21	10		17	9		7	7	f	4	4	f	10	10			17	17	c d
	Low-Two (1-2)	58	14	35	16		23	12		10	10		15	15		19	19			14	14	
⊙	Average	408	3,8	219	3,8		189	3,9		104	4,0	d	102	3,6	c f	100	3,8			102	4,0	d
	StDev	408	1,2	219	1,3		189	1,1		104	1,1		102	1,0		100	1,3			102	1,3	

		TOTAL		Wave						Country											
				Wave 1			Wave 2			Germany			United Kingdom			Italy			Spain		
				a			b			c			d			e			f		
				Abs.	% / ø	Sign.	Abs.	% / ø	Sign.	Abs.	% / ø	Sign.	Abs.	% / ø	Sign.	Abs.	% / ø	Sign.	Abs.	% / ø	Sign.
1007	Q7*1: For each of the following treatment options, how do you estimate the treatment's acceptability over the next six months?																				
	OVERVIEW OF TOP-TWO																				
	BASIS	408	100	219	100		189	100		104	100		102	100		100	100		102	100	
7_1	AT-II antagonists	113	28	55	25		58	31		34	33	d f	21	21	c e	37	37	d f	21	21	c e
7_2	ACE inhibitors	72	18	47	21	b	25	13	a	11	11	e	15	15	e	26	26	c d	20	20	
7_3	Beta blockers	69	17	36	16		33	17		11	11	f	13	13	f	20	20		25	25	c d
7_5	Calcium channel blockers	65	16	32	15		33	17		18	17		9	9	f	16	16		22	22	d
7_4	Diuretics	38	9	21	10		17	9		7	7	f	4	4	f	10	10		17	17	c d
1007	Q7*2: For each of the following treatment options, how do you estimate the treatment's acceptability over the next six months?																				
	OVERVIEW OF AVERAGE																				
	BASIS	408	100	219	100		189	100		104	100		102	100		100	100		102	100	
7_1	AT-II antagonists	408	4,7	219	4,6		189	4,7		104	4,8	d f	102	4,4	c e	100	5,0	d f	102	4,4	c e
7_2	ACE inhibitors	408	4,4	219	4,5		189	4,3		104	4,1	f	102	4,3	f	100	4,5		102	4,6	c d
7_3	Beta blockers	408	4,3	219	4,3		189	4,3		104	4,3		102	4,2	f	100	4,3		102	4,5	d
7_5	Calcium channel blockers	408	4,3	219	4,4		189	4,3		104	4,3		102	4,1	f	100	4,3		102	4,5	d
7_4	Diuretics	408	3,8	219	3,8		189	3,9		104	4,0	d	102	3,6	c f	100	3,8		102	4,0	d

	TOTAL		Wave						Country																
			Wave 1			Wave 2			Germany			United Kingdom			Italy			Spain							
			a			b			c			d			e			f							
			Abs.	% / ø		Abs.	% / ø	Sign.	Abs.	% / ø	Sign.	Abs.	% / ø	Sign.	Abs.	% / ø	Sign.	Abs.	% / ø	Sign.	Abs.	% / ø	Sign.		
QS1: Wave																									
BASIS	408	100	219	100			189	100			104	100			102	100			100	100			102	100	
1 Wave 1	219	54	219	100	b	-	-	-	a		55	53			46	45	f		56	56			62	61	d
2 Wave 2	189	46	-	-	b		189	100	a		49	47			56	55	f		44	44			40	39	d
QS2: Country																									
BASIS	408	100	219	100			189	100			104	100			102	100			100	100			102	100	
1 Germany	104	25	55	25			49	26			104	100	d e f		-	-	c		-	-	c		-	-	c
2 United Kingdom	102	25	46	21	b		56	30	a		-	-	d		102	100	c e f		-	-	d		-	-	d
3 Italy	100	25	56	26			44	23			-	-	e		-	-	e		100	100	c d f		-	-	e
4 Spain	102	25	62	28			40	21			-	-	f		-	-	f		-	-	f		102	100	c d e

Questions or ideas?

Just ask!



This table was compiled using the SmartTabulator 2.0 tabulation software